During the last session, Lifecore Biomedical Inc (NASDAQ:LFCR)’s traded shares were 0.39 million, with the beta value of the company hitting 0.95. At the end of the trading day, the stock’s price was $5.00, reflecting an intraday loss of -11.03% or -$0.62. The 52-week high for the LFCR share is $8.90, that puts it down -78.0 from that peak though still a striking 26.4% gain since the share price plummeted to a 52-week low of $3.68. The company’s market capitalization is $154.50M, and the average intraday trading volume over the past 10 days was 0.21 million shares, and the average trade volume was 298.92K shares over the past three months.
Lifecore Biomedical Inc (NASDAQ:LFCR) trade information
Lifecore Biomedical Inc (LFCR) registered a -11.03% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -11.03% in intraday trading to $5.00, hitting a weekly high. The stock’s 5-day price performance is -3.47%, and it has moved by -12.43% in 30 days. Based on these gigs, the overall price performance for the year is -38.42%. The short interest in Lifecore Biomedical Inc (NASDAQ:LFCR) is 2.87 million shares and it means that shorts have 9.44 day(s) to cover.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The consensus price target of analysts on Wall Street is $8, which implies an increase of 37.5% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $8 and $8 respectively. As a result, LFCR is trading at a discount of -60.0% off the target high and -60.0% off the low.
Lifecore Biomedical Inc (LFCR) estimates and forecasts
Statistics show that Lifecore Biomedical Inc has underperformed its competitors in share price, compared to the industry in which it operates. Lifecore Biomedical Inc (LFCR) shares have gone down -0.79% during the last six months, with a year-to-date growth rate less than the industry average at -50.00% against 17.30. In the rating firms’ projections, revenue will decrease -0.50% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 23.19M as predicted by 3 analyst(s). Meanwhile, a consensus of 3 analyst(s) estimates revenue growth to 30.18M by the end of current fiscal year.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 86.82%. While earnings are projected to return -414.58% in 2024, the next five years will return 10.00% per annum.
LFCR Dividends
Lifecore Biomedical Inc is due to release its next quarterly earnings on 2024-Aug-26. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Lifecore Biomedical Inc (NASDAQ:LFCR)’s Major holders
Lifecore Biomedical Inc insiders own 6.67% of total outstanding shares while institutional holders control 67.76%, with the float percentage being 72.60%.
